Publication Name	World Journal of Gastroenterology
Manuscript ID	17982
Country	Japan

Received	2015-04-01 16:42
Peer-Review Started	2015-04-02 14:43
To Make the First Decision	2015-06-02 15:29
Return for Revision	2015-06-07 17:55
Revised	2015-06-20 16:58
Second Decision	2015-07-27 20:14
Accepted by Journal Editor-in-Chief	2015-07-29 09:38
Accepted by Executive Editor-in-Chief	2015-08-25 18:15
Articles in Press	2015-08-25 18:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-31 14:31
Publish the Manuscript Online	2015-09-28 11:42

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations
Manuscript Source	Invited Manuscript
All Author List	Shunsuke Mori and Shigetoshi Fujiyama
Funding Agency and Grant Number	Funding Agency Grant Number Research funds from the National Hospital Organization, Japan
Corresponding Author	Shunsuke Mori, MD, PhD, Department of Rheumatology, Clinical Research Center for Rheumatic Diseases, NHO Kumamoto Saishunsou National Hospital, 2659 Suya, Kohshi, Kumamoto 861-1196, Japan. moris@saisyunsou1.hosp.go.jp
Key Words	Hepatitis B virus; Antirheumatic therapy; Resolved hepatitis B virus infection; Occult hepatitis B virus carrier; Reactivation
Core Tip	In the literature, the prevalence of resolved hepatitis B virus (HBV) infection varied in rheumatic disease patients, ranging from 7.3% to 66%, which seems to be related directly to the general prevalence of HBV infection in the respective geographic areas. When calculated using data from observational cohort studies, the incidence rate was 1.7% in rheumatic disease patients receiving biological therapy and 3.2% in those treated with non-biological drugs. In antirheumatic therapy, multiple immunosuppressants are administered during long periods. Optimal frequency and duration of HBV-DNA monitoring and reliable markers for discontinuation of nucleoside analogues remain unclear for rheumatic disease patients with resolved HBV infection.
Publish Date	2015-09-28 11:42
Citation	Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol 2015; 21(36): 10274-10289
URL	http://www.wjgnet.com/1007-9327/full/v21/i36/10274.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i36.10274

Full Article (PDF)	WJG-21-10274.pdf
Full Article (Word)	WJG-21-10274.doc
Manuscript File	17982-Review.doc
Answering Reviewers	17982-Answering reviewers.pdf
Audio Core Tip	17982-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17982-Conflict-of-interest statement.pdf
Copyright License Agreement	17982-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	17982-Language certificate.pdf
Peer-review Report	17982-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	17982-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17982-Scientific misconduct check.pdf
Scientific Editor Work List	17982-Scientific editor work list.pdf